Stock Ratings / Health Care / CLRB / insiders

GTBP (46) TVRD (40) ASBP (33) CALC (47) ⌘ Pro Terminal →

Cellectar Biosciences Inc. (CLRB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are CLRB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CLRB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$1.22 -1.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cellectar Biosciences Inc. (CLRB) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $11.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLRB)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CLRB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CLRB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CLRB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLRB)

✓Walkthrough of CLRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.08%▼ DESCENDING CHANNEL

2026-10-30O $1.20H $1.22L $1.18C $1.22VOL 55.3K

RES: $2.15SUP: $0.82SMA50: $1.89SMA200: $2.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLRB Butterfly Map → + Track CLRB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLRB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLRB)

Health Care Rank #765 of 1016 ⚔️ GTBP vs CLRB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLRB vs. GTBP, TVRD, ASBP, CALC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cellectar Biosciences Inc. (CLRB) ranks #765 by composite RQD confidence (37/100, grade D-) and #883 by equity capitalization ($11.5M). Within this direct 5-issuer industry benchmark cohort, CLRB leads on earnings valuation at N/A trailing P/E, while CLRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CALC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with CLRB at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLRB ACTIVE Cellectar Biosciences Inc.	D-	37/100	—	—	-35.0%	-1.61%	$11.5M	Benchmark Subject
GTBP GT Biopharma Inc.	D	46/100	—	—	-35.0%	+1.63%	$11.5M	/gtbp-vs-clrb →
TVRD Tvardi Therapeutics Inc.	D-	40/100	—	—	-35.0%	-2.73%	$11.5M	/tvrd-vs-clrb →
ASBP Aspire-Lakewood Holdings Inc.	E	33/100	—	-1.9%	-35.0%	-4.50%	$11.9M	/asbp-vs-clrb →
CALC CalciMedica Inc.	D	47/100	—	—	-35.0%	+5.42%	$11.9M	/calc-vs-clrb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001279704

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cellectar Biosciences Inc. (CLRB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$21.8M, operating cash flow of -$23.1M, and free cash flow of -$23.1M (+51.5% YoY). On the balance sheet, CLRB closed FY2025 with $15.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$21.8M	-$23.1M	-$23.1M	$15.0M	—
FY2024 (FY)	2024-12-31	$0	-$44.6M	-$47.6M	-$47.7M	$25.5M	—
FY2023 (FY)	2023-12-31	$0	-$38.0M	-$32.4M	-$32.4M	—	—

3. CLRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cellectar Biosciences Inc. (NASDAQ: CLRB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.22 (-1.61% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CLRB ranks #765 in composite RQD confidence.

How does CLRB compare to GTBP and TVRD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLRB carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M) and TVRD (Tvardi Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $11.5M). Among the 5-stock peer group, CLRB leads on earnings multiple (N/A) while CLRB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLRB?

Per CLRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001279704), Cellectar Biosciences Inc. generated $0 in revenue, -$21.8M in net income, and -$23.1M in free cash flow against $15.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLRB trading relative to its 50-day, 200-day, and 52-week technical levels?

CLRB last traded at $1.22 (-1.61% on volume of 111,915 shares), positioning the stock -35.45% below its 50-day simple moving average ($1.89) and -53.61% below its 200-day simple moving average ($2.63). Across its 52-week range of $1.12 to $4.70, CLRB sits at the 2.8% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.07 to $1.37).

CLRB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are CLRB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies CLRB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: CLRB RQD Cockpit CLRB 12M Forecast CLRB Earnings & Move CLRB Dividends & DRIP CLRB Insiders & 13F CLRB Whale Options CLRB Profit Sankey CLRB News & Why